The combination of anti-CTLA-4 and anti-PD-1 treatment appears to target separate populations of T-cells and has already been approved in hepatocellular carcinoma, melanoma, renal cell carcinoma, and colorectal cancer, with a variety of trials ongoing [113, 114]. Here, CTLA4 is linked to melanoma.